CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of
investigational RNA interference (RNAi) therapeutics, today announced
that Douglas M. Fambrough, Ph.D., president and chief executive officer,
will present at the Stifel 2016 Healthcare Conference on Wednesday,
November 16, 2016, from 3:45-4:25 p.m. ET at the Lotte New York Palace
Hotel in New York.
A live webcast of the presentation can be accessed on the Investors &
Media section on the Dicerna website at www.dicerna.com.
An archived replay of the webcast will be available on the Company's
website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on
the discovery and development of innovative RNA interference
(RNAi)-based therapeutics for rare diseases involving the liver and for
other diseases involving the liver such as chronic liver diseases,
cardiovascular diseases, and viral infectious diseases. The Company is
using its proprietary GalXC™ RNAi technology platform to build a broad
pipeline in these core therapeutic areas. Dicerna is pursuing target
genes where connections between target gene and diseases are well
understood and documented. The Company intends to discover, develop and
commercialize these novel therapeutics either on its own or in
collaboration with pharmaceutical partners.
For more information, please visit www.dicerna.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161109005920/en/
Rx Communications Group
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media